Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2000

View Archived Issues

MDS Nordion to manufacture Altropane diagnostic agent

Lynx Therapeutics enters partnership to identify diabetes-associated SNPs

Dendreon describes therapeutic cancer vaccine technology

NIH offers V1 knockout mice for S. pneumoniae vaccine screening

Peptide vaccines available for licensing from NIH

cDNA clones of tick-borne flavivirus available for licensing from NIH

Suplatast tosilate improves asthma symptoms in a double-blind trial

Malaria incidence and resistance controlled by artesunate-mefloquine treatment

Research links development of type 1 diabetes with inflammation

Mechanism of resistance to ABL tyrosine kinase inhibitor STI-571 explored

Potent, selective human A2B adenosine receptor antagonists reported

Orally active dual NK1/NK2 antagonist synthesized by Schering-Plough

Selective ICAM-1 and E-selectin inhibitors on human endothelial cells explored

Wyeth-Ayerst recommends that certain lots of Norplant not be implanted

Psoriasis therapy proceeds to clinical trials

Interneuron enrolls first patients in phase I/II study of PRO-2000 Gel

Syntheses and SAR presented for DuPont Pharmaceuticals' CRF receptor antagonists

Orphan Medical's Antizol sNDA accepted for filing

FDA approves Santen's levofloxacin eyedrops

Inex's Onco TCS given fast track status

New series of PARP inhibitors claimed by Guilford

Elan and Biogen establish Antegren collaboration agreement

Novel compounds useful for neurological disorders claimed by AstraZeneca

Seven key sessions and symposia from XXII ESC Congress available to Daily Essentials readers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...